RL34 Subgroup Claim: When to Accept?
*Rajeshwari Sridhara, U.S. Food and Drug Administration
Subgroup analyses are conducted routinely whether they are specified in the protocol or not. The results from such analyses become contentious particularly if the primary analysis in all randomized patients has not demonstrated efficacy. This roundtable will discuss the pros and cons of subgroup analyses when they were (1) planned vs. not planned, (2) observed in one study vs. multiple studies, and (3) in non-inferiority vs. superiority studies.
April 30 - May 22, 2013
Invited Abstract Submission Open
June 4, 2013
Online Registration Opens
August 9 - August 23, 2013
Invited Abstract Editing
August 23, 2013
Short Course materials due from Instructors
August 26, 2013
September 9, 2013
Cancellation Deadline and Registration Closes @ 11:59 pm EDT
September 16 - September 18, 2013
Marriott Wardman Park, Washington, DC